Literature DB >> 27744711

Therapy of antihistamine-resistant chronic spontaneous urticaria.

Justin Greiwe1,2, Jonathan A Bernstein1,2.   

Abstract

INTRODUCTION: Chronic urticaria affects up to 1-3% of the general population and contributes to significant direct and indirect medical costs as well as decreased quality of life, which has a significant economic impact on our health care system. Areas covered: Given the prevalence of this condition on a large sector of the population, finding lasting relief for refractory cases is essential and is the focus of this review. Expert commentary: The choice of appropriate therapy in chronic refractory urticaria is not a 'one-size fits all' approach. Treatment should take multiple factors into consideration including the chronicity of hives, presence of physical urticaria, type of cellular infiltrate on skin histopathology, patient age, concomitant comorbid conditions, as well as patient preference and cost.

Entities:  

Keywords:  Chronic urticaria; anti-inflammatory agents; antihistamine resistant; cyclosporine; omalizumab

Mesh:

Substances:

Year:  2016        PMID: 27744711     DOI: 10.1080/1744666X.2017.1249467

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  1 in total

1.  Omalizumab for urticaria treatment in clinical practice: a case series.

Authors:  Aleksandra Lesiak; Igor A Bednarski; Anna Maćkowska; Zuzanna Łukasik; Anna Woźniacka; Irmina Olejniczak-Staruch; Joanna Narbutt
Journal:  Postepy Dermatol Alergol       Date:  2018-08-21       Impact factor: 1.837

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.